While in the hospital, she showed no insight and felt that there was nothing wrong. She wanted to walk nude, arguing that there are nude beaches in the world, and therefore, nudity should be acceptable in the psychiatric unit. She refused to take any medication, again claiming that there was nothing wrong with her. She became hostile, and I had to use intramuscular benzodiazepine treatment. Her Young Mania Rating Scale (YMRS) score was 48, which is consistent with severe mania. She was started back on gabapentin and also received risperidone liquid 1 mg twice daily. After 2 doses of risperidone, which were administered with difficulty, she showed a dramatic response. Her psychomotor excitement and inappropriate sexual behaviours totally disappeared, and she started to sleep well. Two days later, her YMRS score was was 17.
Although antipsychotics are frequently used to control psychotic agitation, risperidone was found to be unique in this case. Certainly, it stabilized her mood within a couple of days and with only 2 doses. Given this case report, it may be wise to consider risperidone liquid as a first choice in the case of acute mania, in addition to any other mood stabilizer.
TM Abraham, MD, FRCPC Welland, Ontario
Methylphenidate and the Cytochrome P450 System
Dear Editor:
I reviewed with interest the case report in your journal describing unexpected grand mal seizures in a 14-year-old boy treated for attention-deficit hyperactivity disorder (ADHD) with methylphenidate (MPH) 60 mg daily, to which buproprion was added (1). The author notes, "it is also possible that the risk of seizures was amplified by the combination of buproprion and methylphenidate" (1, p 790).
This case report is of concern, insofar as a combination of buproprion and MPH, if known to be safe, would be a sensible augmented regimen for treatmentresistant or treatment-refractory cases of ADHD (2) and perhaps even depressive disorders (3).
However, the literature suggests a mechanism for possible deleterious interaction between these 2 agents; namely, it is possible that MPH inhibits a hepatic isoenzyme that contributes to the metabolic clearance of buproprion from the body. Several authors have alluded to methylphenidate's capacity to inhibit the degradation of cyclic antidepressants (4) (5) (6) . MPH has been cited as an inhibitor of CYP2D6 (7) . It may also inhibit other hepatic enzymes, including perhaps CYP2B6, the isoenzyme predominantly responsible for the metabolism of buproprion (8), or other enzymes not currently known to help clear buproprion.
The net result of such a possible interaction could be higher buproprion plasma levels and greater risk of seizure. This risk may be compounded by buproprion's own inherently greater epileptogenic potential and the rapidity of its time to peak levels in both the older formulation and the newer slow release (SR) compound (9). It has been theorized that "rapidity of dose escalation" is a factor in the capacity for antidepressants to cause seizure (10). Peak plasma level occurs within 2 hours for buproprion (traditional preparation) and within 3 hours for the newer SR preparation after oral ingestion. This is 2 to 3 times faster than, for example, "time to peak plasma level" for fluoxetine, which requires 6 to 8 hours (9). By reducing metabolic clearance, a coadministered hepatic enzyme inhibitor such as MPH may accelerate time to peak and also amplify peak plasma concentrations, both of which have been implicated as risks in buproprioninduced seizures (10).
